These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38999963)

  • 1. Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast Cancer by Single-Cell Transcriptomic Analysis.
    Foutadakis S; Kordias D; Vatsellas G; Magklara A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers.
    Kabeer F; Tran H; Andronescu M; Singh G; Lee H; Salehi S; Wang B; Biele J; Brimhall J; Gee D; Cerda V; O'Flanagan C; Algara T; Kono T; Beatty S; Zaikova E; Lai D; Lee E; Moore R; Mungall AJ; ; Williams MJ; Roth A; Campbell KR; Shah SP; Aparicio S
    Genome Biol; 2024 Jul; 25(1):191. PubMed ID: 39026273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line.
    Moreira MP; Franco EP; Barros BAF; Anjos BRD; Almada DG; Barbosa INT; Braga LDC; Cassali GD; Silva LM
    Biochem Biophys Res Commun; 2024 Nov; 734():150765. PubMed ID: 39357337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/β-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer.
    Shome R; Sen P; Sarkar S; Ghosh SS
    Exp Cell Res; 2024 May; 438(1):114032. PubMed ID: 38583856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
    Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
    Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
    Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
    Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell transcriptome sequencing reveals SPP1-CD44-mediated macrophage-tumor cell interactions drive chemoresistance in TNBC.
    Liu F; Zhang J; Gu X; Guo Q; Guo W
    J Cell Mol Med; 2024 Jul; 28(13):e18525. PubMed ID: 38982317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 11. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
    Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
    Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
    Gao W; Sun L; Gai J; Cao Y; Zhang S
    PLoS One; 2024; 19(1):e0297260. PubMed ID: 38227591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing.
    Zhang H; Sun Y; Du X
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):290. PubMed ID: 39206896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
    Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
    Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
    Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
    Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
    Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
    Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.